## **Core Concept**
Alkaptonuria is a rare genetic disorder caused by a deficiency of the enzyme **homogentisate 1,2-dioxygenase**. This enzyme is crucial in the breakdown pathway of the amino acids tyrosine and phenylalanine. The deficiency leads to the accumulation of **homogentisic acid**, which causes the urine to turn black upon standing and leads to ochronosis, a condition characterized by the deposition of a pigment in connective tissues.

## **Why the Correct Answer is Right**
The correct answer involves the use of **Nitisinone (C)**, a drug that inhibits the enzyme **4-hydroxyphenylpyruvate dioxygenase**. By inhibiting this enzyme, nitisinone reduces the production of homogentisic acid from tyrosine, thereby decreasing its accumulation and the subsequent ochronotic pigment deposition. This approach addresses the biochemical defect indirectly and has been explored as a therapeutic strategy for managing Alkaptonuria.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because it does not correspond to a recognized treatment for Alkaptonuria.
- **Option B:** Similarly, this option does not represent a standard or experimental treatment for the condition.
- **Option D:** This option is also incorrect as it does not relate to a known therapeutic approach for Alkaptonuria.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that Alkaptonuria is one of the few disorders where a specific dietary restriction or a drug like **Nitisinone** can modify the disease course. The classic black urine and ochronotic pigmentation are diagnostic hallmarks. Early diagnosis and intervention can potentially mitigate some of the long-term complications associated with this condition.

## **Correct Answer:** C. Nitisinone.